下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Major Shareholder Sells $1,248,192.66 in Stock
内部出售:特雷维治疗公司(纳斯达克代码:TRVI)大股东出售价值1,248,192.66美元的股票

Defense World ·  {{timeTz}}

Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction on Friday, July 1st. The shares were sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now directly owns 3,888,452 shares of the company's stock, valued at $11,120,972.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

特雷维治疗公司(纳斯达克代码:TRVI-GET评级)的大股东TPG GP A,LLC在7月1日(星期五)的一笔交易中出售了436,431股特雷维治疗公司的股票。这些股票的平均价格为2.86美元,总价值为1,248,192.66美元。交易完成后,这位内部人士现在直接持有该公司3888,452股股票,价值11,120,972.72美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站访问。持有公司10%或以上股份的大股东必须披露他们与美国证券交易委员会的交易。

Tpg Gp A, Llc also recently made the following trade(s):

TPG GP A,LLC最近还进行了以下交易:

Get
到达
Trevi Therapeutics
特雷维治疗公司
alerts:
警报:
  • On Tuesday, July 5th, Tpg Gp A, Llc sold 63,569 shares of Trevi Therapeutics stock. The shares were sold at an average price of $3.11, for a total value of $197,699.59.
  • On Wednesday, June 29th, Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.74, for a total value of $126,390.72.
  • On Monday, May 2nd, Tpg Gp A, Llc sold 600 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.70, for a total value of $1,620.00.
  • On Thursday, April 28th, Tpg Gp A, Llc sold 7,271 shares of Trevi Therapeutics stock. The shares were sold at an average price of $2.77, for a total value of $20,140.67.
  • 7月5日,星期二,TPG GP A,LLC出售了63,569股Trevi治疗公司的股票。这些股票的平均价格为3.11美元,总价值为197699.59美元。
  • 6月29日,星期三,TPG GP A,LLC出售了46,128股Trevi Treeutics股票。这些股票的平均价格为2.74美元,总价值为126,390.72美元。
  • 5月2日,星期一,TPG GP A,LLC出售了600股Trevi治疗公司的股票。这些股票的平均价格为2.70美元,总价值为1,620.00美元。
  • 4月28日,星期四,TPG GP A,LLC出售了7271股Trevi治疗公司的股票。这些股票的平均价格为2.77美元,总价值为20,140.67美元。

Shares of NASDAQ:TRVI opened at $3.79 on Friday. The stock has a market capitalization of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18. Trevi Therapeutics, Inc. has a 1-year low of $0.46 and a 1-year high of $3.86. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $2.40 and a two-hundred day moving average price of $1.74.

纳斯达克:天猫国际周五开盘报3.79美元。该股市值为1.4664亿美元,市盈率为-2.81,贝塔系数为0.18。Trevi Treeutics,Inc.的一年低点为0.46美元,一年高位为3.86美元。该公司的流动比率为2.32,速动比率为2.32,债务权益比率为0.67。该业务的50日移动均线价格为2.40美元,200日移动均线价格为1.74美元。

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.07. During the same period last year, the business earned ($0.43) EPS. As a group, equities analysts predict that Trevi Therapeutics, Inc. will post -0.81 EPS for the current year.
特雷维治疗公司(纳斯达克代码:TRVI-GET Rating)最近一次公布财报是在5月12日星期四。该公司公布本季度每股收益(EPS)为0.24美元,比普遍预期的0.31美元高出0.07美元。去年同期,该业务每股收益为0.43美元。股票分析师预测,作为一个整体,Trevi治疗公司本年度的每股收益将达到0.81美元。

A number of research analysts recently issued reports on TRVI shares. Oppenheimer lifted their price target on Trevi Therapeutics to $12.00 in a report on Monday. Needham & Company LLC lifted their price target on Trevi Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, June 29th. Finally, Aegis assumed coverage on Trevi Therapeutics in a report on Tuesday, March 29th. They issued a "buy" rating and a $10.00 price target for the company.

一些研究分析师最近发布了关于TRVI股票的报告。奥本海默在周一的一份报告中将他们对Trevi治疗公司的目标价上调至12.00美元。Needham&Company LLC在6月29日星期三的一份报告中将Trevi治疗公司的目标价从8.00美元上调至10.00美元,并给予该公司“买入”评级。最后,宙斯盾在3月29日星期二的一份报告中假定了对Trevi治疗公司的报道。他们对该公司的评级为“买入”,目标价为10.00美元。

Several institutional investors have recently bought and sold shares of TRVI. Commonwealth Equity Services LLC acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $33,000. WealthTrust Axiom LLC grew its position in shares of Trevi Therapeutics by 245.6% during the 1st quarter. WealthTrust Axiom LLC now owns 98,500 shares of the company's stock worth $216,000 after buying an additional 70,000 shares during the period. MAI Capital Management acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $3,391,000. Vanguard Group Inc. grew its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock worth $336,000 after buying an additional 10,780 shares during the period. Finally, State Street Corp acquired a new position in shares of Trevi Therapeutics during the 1st quarter worth about $81,000. Institutional investors own 75.34% of the company's stock.

几家机构投资者最近买卖了TRVI的股票。英联邦股权服务有限责任公司在第一季度收购了Trevi治疗公司的新股份,价值约33,000美元。第一季度,WealthTrust Axiom LLC在特雷维治疗公司的股票持有量增加了245.6%。WealthTrust Axiom LLC现在拥有98,500股该公司的股票,价值21.6万美元,在此期间又购买了70,000股。Mai资本管理公司在第一季度收购了Trevi治疗公司的新股票,价值约3391,000美元。第一季度,先锋集团在Trevi治疗公司的股票持有量增加了7.6%。先锋集团现在持有152,831股该公司股票,价值336,000美元,在此期间又购买了10,780股。最后,道富银行在第一季度收购了Trevi治疗公司股票的新头寸,价值约81,000美元。机构投资者持有该公司75.34%的股票。

About Trevi Therapeutics (Get Rating)

特雷维治疗公司简介(获取评级)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Trevi治疗公司是一家临床阶段的生物制药公司,专注于Haduvio的开发和商业化,以治疗严重的神经介导性疾病。该公司正在开发Haduvio,这是一种纳布芬的口服缓释制剂,处于IIb/III期临床试验,用于治疗特发性肺纤维化患者的慢性瘙痒和慢性咳嗽。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
  • 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
  • Credo Technology Stock is Rebounding
  • Investing In Preferred Stock vs. Common Stock
  • Profiting From 52 Week Low Stocks
  • Three Cheap Stocks The Insiders Are Buying
  • 免费获取StockNews.com关于特雷维治疗公司(TRVI)的研究报告
  • 3种食品杂货股可以帮助缓解通胀
  • 信实科技股正在反弹
  • 投资优先股与普通股
  • 从52周低点的股票中获利
  • 内部人士正在买入的三只廉价股票

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受Trevi治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Trevi治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。